RESUMEN
Antibodies from patients with Chagas heart disease and monoclonal antibodies (or mAb) to the carboxy-terminal end (B cell epitope R13) of the ribosomal P2beta protein of Trypanosoma cruzi (TcP2beta) cross-react with the beta1 adrenergic receptor (beta1-AR). Two single-chain Fv fragments (scFv) C5 and B7 derived from the variable regions of the anti-R13 mAb 17.2 were expressed. scFv C5 was a dimer and bound to TcP2beta with an affinity of K(d) = 8 nM, whereas scFv B7 was monomeric and had less affinity than scFv C5 for TcP2beta, K(d) = 46 nM. The affinity constant of scFv C5 to the second extracellular loop of the human beta1-AR was of 10 microM. Moreover, scFv C5 induced an increase in cAMP levels of CHO-K cells transfected with the human beta1-AR; scFv B7 had no effect but blocked isoproterenol stimulation. The agonist-like activity of scFv C5 and the antagonist activity of scFv B7 were both confirmed in vivo on heart beating frequency after their passive transfer to mice. Molecular modeling of the variable region of mAb 17.2 indicated which amino acids were likely to be involved in recognizing both peptide EDDDMGFGLF, derived from the R13 epitope of TcP2beta, and peptide ESDEARRCYN from the second extracellular loop of the human beta1-AR. It is plausible that the recently described cross-reaction of mAb 17.2 with rhodopsin can also be explained by this model. The physiological effects of this type of anti-T. cruzi antibodies may increase the liability of patients with Chagas disease.
Asunto(s)
Anticuerpos Antiprotozoarios/inmunología , Enfermedad de Chagas/inmunología , Fosfoproteínas/inmunología , Proteínas Protozoarias/inmunología , Receptores Adrenérgicos beta 1/inmunología , Proteínas Ribosómicas/inmunología , Trypanosoma cruzi/inmunología , Secuencia de Aminoácidos , Animales , Secuencia de Bases , Células CHO , Cricetinae , Reacciones Cruzadas , Cartilla de ADN , Frecuencia Cardíaca , Humanos , Fragmentos de Inmunoglobulinas/inmunología , Región Variable de Inmunoglobulina/genética , Ratones , Datos de Secuencia Molecular , Fragmentos de Péptidos/química , Fragmentos de Péptidos/inmunología , Reacción en Cadena de la Polimerasa , Proteínas Protozoarias/genética , RatasRESUMEN
Monoclonal antibodies were raised against a recombinant ribosomal P2beta protein of Trypanosoma cruzi. One of these reacted with the C terminus of this protein (peptide R13, EEEDDDMGFGLFD) and epitope mapping confirmed that this epitope was the same as the one defined by the serum of immunized mice, and similar to the previously described chronic Chagas' heart disease (cChHD) anti-P epitope. Western blotting showed that the monoclonal antibody recognized the parasite ribosomal P proteins, as well as the human ribosomal P proteins. Electron microscopy showed that it stained different structures in parasite and human cells. Interestingly, surface plasmon resonance measurements indicated that the affinity for the parasite ribosomal P protein epitope (R13) was five times higher than for its human counterpart (peptide H13, EESDDDMGFGLFD). Since the human epitope contained an acidic region (EESDD) similar to the AESDE peptide recognized by cChHD patients in the second extra-cellular loop of the human beta1-adrenergic receptor, the biological activity of the antibody was assessed on neonatal rat cardiomyocytes in culture. The monoclonal antibody had an agonist-like effect. These results, together with the fact that the monoclonal reacted in Western blots with the different isoforms of the heart beta1-adrenergic receptor, confirm the possible pathogenic role of antibodies against the parasite ribosomal P protein based on their cross-reaction with the human beta1-adrenergic receptor.
Asunto(s)
Anticuerpos Antiprotozoarios/inmunología , Autoanticuerpos/inmunología , Proteínas Protozoarias/inmunología , Receptores Adrenérgicos beta 1/inmunología , Proteínas Ribosómicas/inmunología , Trypanosoma cruzi/inmunología , Animales , Anticuerpos Monoclonales/inmunología , Especificidad de Anticuerpos , Células Cultivadas , Cardiomiopatía Chagásica/inmunología , Reacciones Cruzadas , Células HeLa , Humanos , Epítopos Inmunodominantes/inmunología , Miocardio/inmunología , Conejos , Ratas , Ratas Wistar , Trypanosoma cruzi/ultraestructuraRESUMEN
A complement regulatory protein (CRP) of Trypanosoma cruzi was evaluated as a vaccine candidate in a murine model of experimental T. cruzi infection. Recombinant CRP derived from an Escherichia coli expression system and a plasmid encoding the full-length crp structural gene under the control of a eukaryotic promoter were used to immunize BALB/c mice. Immunization with both protein and DNA vaccines resulted in a Th1-type T-cell response, comparable antibody titers, and similar immunoglobulin G isotype profiles. Only mice immunized with the crp DNA plasmid produced antibodies capable of lysing the parasites in the presence of complement and were protected against a lethal challenge with T. cruzi trypomastigotes. These results demonstrate the superiority of DNA immunization over protein immunization with the recombinant CRP. The work also supports the further investigation of CRP as a component of a multigene, anti-T. cruzi DNA vaccine.
Asunto(s)
Enfermedad de Chagas/prevención & control , Proteínas Inactivadoras de Complemento/inmunología , Glicoproteínas de Membrana/inmunología , Proteínas Protozoarias/inmunología , Vacunas Antiprotozoos/inmunología , Trypanosoma cruzi/inmunología , Vacunas de ADN/inmunología , Animales , Anticuerpos Antiprotozoarios/sangre , Citocinas/biosíntesis , Inmunización , Glicoproteínas de Membrana/genética , Ratones , Ratones Endogámicos BALB C , Ratones Endogámicos C3H , Proteínas Protozoarias/genética , Vacunas Sintéticas/inmunologíaRESUMEN
Antibodies against the Trypanosoma cruzi ribosomal P2beta protein (TcP2beta) have been associated with the chronic cardiac pathology of Chagas' disease in humans. Using synthetic peptides spanning the entire TcP2beta molecule, we investigated their epitope recognition by antibodies from mice chronically infected with T. cruzi and from mice immunized with two recombinant TcP2betas. We found clear differences in epitope recognition between antibodies from T. cruzi-infected mice and mice immunized with two different recombinant TcP2betas associated with different schedules of immunization. Major epitopes recognized by antibodies from mice immunized with recombinant glutathione S-transferase (GST) or histidine (Hist) fusion TcP2beta (GST-TcP2beta or Hist-TcP2beta) are located in the central and hinge regions of the molecule. Nevertheless, mice immunized with Hist-TcP2beta were also able to elicit antibodies against the TcP2beta C terminus, a region which is highly conserved in both T. cruzi and mammal ribosomal P proteins. Strikingly, antibodies from infected animals recognized only the TcP2beta C terminus. By using these antisera with distinct profiles of epitope recognition, it could be shown that only C terminus-specific antibodies were able to increase the beating frequency of cardiomyocytes from neonatal rats in vitro by selective stimulation of the beta1-adrenergic receptor. Thus, antibodies against the TcP2beta C terminus elicited in the absence of infection are able to modulate a functional activity of host cells through a molecular mimicry mechanism.
Asunto(s)
Anticuerpos Antiprotozoarios/inmunología , Corazón/fisiología , Fosfoproteínas/inmunología , Secuencia de Aminoácidos , Animales , Mapeo Epitopo , Inmunización , Ratones , Ratones Endogámicos C3H , Datos de Secuencia Molecular , Fosfoproteínas/química , Estructura Secundaria de Proteína , Ratas , Ratas Wistar , Receptores Adrenérgicos beta 2/fisiología , Proteínas RibosómicasRESUMEN
An enzyme linked immunosorbent assay (ELISA) was developed for detecting IgM and IgG antibodies against Trypanosoma cruzi in blood bank donors from endemic or nonendemic areas. A crude extract of trypomastigotes from cultures was used as antigen. A total of 494 serum samples from patients with acute, congenital, or chronic form of Chagas' disease, and from healthy French individuals were studied. The sensitivity of the ELISA was determined with 89 serum samples from chagasic patients and was evaluated to 98.8%. The specificity was determined with 405 serum samples from French blood transfusion centers donors and evaluated to 98.3%. Two hundred and eighty-five serum samples from blood donors from Argentina and Brazil were also tested. Furthermore, in order to assess the absence of cross-reactivity with other protozoan infections, we studied 86 serum samples including (i) 32 individuals with cutaneous leishmaniasis living in a T. cruzi endemic region of Bolivia, and (ii) 54 patients from nonendemic area for Chagas' disease, 19 of them with kala-azar and 35 others with malaria.
Asunto(s)
Anticuerpos Antiprotozoarios/sangre , Enfermedad de Chagas/diagnóstico , Ensayo de Inmunoadsorción Enzimática/métodos , Trypanosoma cruzi/inmunología , Animales , Anticuerpos Antiprotozoarios/inmunología , Donantes de Sangre , Enfermedad de Chagas/epidemiología , Enfermedad de Chagas/inmunología , Enfermedad de Chagas/prevención & control , Enfermedades Endémicas , Humanos , Inmunoglobulina G/sangre , Inmunoglobulina M/sangre , Sensibilidad y EspecificidadRESUMEN
A large field study has been performed in the Cochabamba region of Bolivia with the aim of comparing the polymerase chain reaction (PCR) with other diagnostic methods for Chagas' disease. The amplification of Trypanosoma cruzi-specific kinetoplast DNA sequences in blood samples was compared with classical serological methods, specific IgM detection and direct parasite visualization for 268 school children in a single village where Chagas' disease transmission is active. Of 113 children positive by classical serology or buffy coat examination, 106 were detected by PCR (sensitivity: 93.8%). We did not observe any significant difference of PCR sensitivity between initial (IgM and/or buffy coat positive) and indeterminate stage (only IgG positive) patients. Among the remaining 155 children unconfirmed as chagasic (who were either only IgM positive, IgG-, IgM-, and buffy coat-negative) only 1 case was PCR positive. This case may be due to DNA contamination, or to a very recent infection not detected otherwise, or to specific immune depression. These results show that PCR is a very sensitive parasitological test for Chagas' disease in active transmission regions. The future follow-up of the possibly infected patients who were only IgM-positive should clarify the interest of PCR and IgM tests in the detection of starting infections.
Asunto(s)
Enfermedad de Chagas/diagnóstico , Reacción en Cadena de la Polimerasa/métodos , Adolescente , Anticuerpos Antiprotozoarios/sangre , Bolivia/epidemiología , Enfermedad de Chagas/epidemiología , Enfermedad de Chagas/parasitología , Niño , Preescolar , Humanos , Inmunoglobulina G/sangre , Inmunoglobulina M/sangre , Lactante , Leucocitos/parasitología , Prevalencia , Población Rural , Sensibilidad y Especificidad , Pruebas SerológicasRESUMEN
Chagas' disease (American Trypanosomiasis) is caused by infection with the haemoflagellate parasite Trypanosoma cruzi, which is transmitted from animals to man by the Reduviidae bug. The human disease is characterized by two phases. In the first (acute phase) parasitaemia is high and general symptoms variable. The next, which is lifelong (chronic phase), is characterized by inflammatory lesions in cardiac and skeletal muscle, gastrointestinal, the autonomic nervous system. Parasites are difficult to detect in blood and affected tissues. Lesions within the autonomic nervous system, lead to development of cardiomyopathy, megaoesophagus and megacolon. The discrepancy between the profusion of inflammatory lesions and the absence of parasites suggests the development of autoimmunity probably of a cell-mediated type. Several autoimmune abnormalities have been noted during Trypanosoma cruzi infection. These include suppression of the specific response to autoantibodies directed against antigens located in the endocardium and in nerves, and development of cell-mediated immunity against host antigens (cytotoxic T- and delayed type hypersensitivity T-cells). These autoimmune disorders are thought to be responsible for much of the pathological damage in chronic Chagas' disease.